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A B S T R A C T
Acne patients are subject to different degree of psychosocial distress. The emotional impact of acne vulgaris due to dis-
figurement caused by the disease is undisputed. Most common reactions to the acne are depression and anxiety. The use
of isotretinoin, one of the most effective options in acne treatment, increases depression symptoms. The aim of this study
was to investigate the psychological status of the patients with moderate to severe acne and to compare patients treated
with isotretinoin with patients treated with vitamin C. A total of 85 patients suffering from acne vulgaris were included
in the study. The results of this study do not find a significant correlation between the use of isotretinoin and the psycho-
logical effects of the drug.
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Introduction
Acne vulgaris is based on follicular keratosis of seba-
ceous glands that occurs mainly during puberty, but also
during adolescence. The origin of the acne is complex and
not completely understood. At least 4 pathophysiologic
events take place: androgen-mediated stimulation of se-
baceous gland activity, abnormal keratinization leading
to follicular plugging (comedonic formation), prolifera-
tion of the bacterium Propionibacterium acnes within
the follicle, and inflammation1. It belongs to the most
frequent clinical pictures in dermatology and can be a
painful and disfiguring disease. Acne is equally observed
in people of both sexes, severer courses occurring primar-
ily in young males2.
Isotretinoin, a naturally occurring metabolite of vita-
min A, inhibits sebaceous gland differentiation and pro-
liferation, reduces sebaceous gland size, suppresses se-
bum production and normalizes follicular epithelial des-
quamation. Isotretinoin is the most effective treatment
indicated in severe and acne unresponsive to other thera-
pies. It is used over a 4 to 6 month treatment period.
Some reviews examined the issue of reported cases of
depression and anxiety with isotretinoin. Epidemiologi-
cal evidence for an association between isotretinoin and
depression is currently lacking3. While the role of psycho-
somatic components in the pathogenesis of acne is
differently assessed, secondary emotional impairment
due to disfigurement by the disease is almost undispu-
ted4. Although the knowledge concerning the psycho-
emotional implications of acne has been constrained by
poor methodological design5 few studies have assessed
the impact of effective physical intervention upon the
psychoemotional functioning of patients6.
The aim of the present investigation was to determine
the emotional impact of acne and the effect of the treat-
ment with isotretinoin.
Patients and Methods
The prospective study was conducted at the Depart-
ment for Dermatology and Venerology University Clini-
cal Hospital Mostar and included 85 patients. The partic-
ipants were outpatients suffering from moderate acne,
aged from 13 to 25 years, average 17.4, and others suffer-
ing from severe acne aged from 14 to 24, average 18.2.
Acne patients were treated with isotretinoin 1 mg/kg per
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day, and control group with vitamin C 500 mg per day.
There were 46 moderate acne patients (20 treated with
isotretinoin and 26 patients were control group) and 39
severe acne patients (21 treated with isotretinoin, and 18
were control group). All participants provided written in-
formed consent. Exclusion criteria included prior use of
or allergy to isotretinoin, and pregnancy in female partic-
ipants. In the isotretinoin group, all female participants
subjected of childbearing potential used 2 forms of birth
control. The clinical classification of acne was done ac-
cording to Plewig and Kligman7. All patients underwent
an assessment before the treatment, during the 8 week
treatment and at the end of the 4 week after finished
treatment. Consenting participants completed the same
psychometric instruments, standardized with optimal
psychometric characteristics. None had any other severe
dermatological or psychiatric diseases. The psychologist,
as a member of the team, conducted psychological testing
and interview.
Following questionnaires were used in the research to
assess psychological state of our patients:
»Assessments of the Psychological and Social Effects«
of Acne (APSEA): specific questionnaire consisted of 15
answers. Sensitive scale ranging from 10 to 117 assess-
ment the psychosocial effects of acne. The test is impor-
tant for monitoring disorder on psychological status dur-
ing therapy.
»Beck Depression Inventory« (BDI): is a widely used
clinical and research instrument to determine the sever-
ity of depressive symptoms8. It is a 21 item self-report
rating inventory measuring characteristic in patients
older than 13 years. The scores range from 0 to 63, over
30 indicates a clinical depressive disorder9.
»State Trait Anxiety Inventory« (STAI): is an original
questionnaire for measuring state (STAIs) and trait
(STAIt) anxiety. It consists of two questionnaires with 20
statements. State anxiety estimates tension, anxiety and
stress. Trait anxiety measures the degree of anxiety as a
relatively stabile personal characteristics and long last-
ing anxiety which is not related to the specific situa-
tions. The score on each of questionnaire are given on a
5-point Libert scale. Minimum result is 0, and maxi-
mum is 80. The questionnaire is often use in clinical trials
and practice.
»Measure of Psychological Stress« (MPS): is question-
naire which measure level of experienced stress regard-
less of the specific experience that has caused the stress.
It consists of 48 questions. The total result is a sum of es-
timations given for all 48 statements which is then pre-
sented on a scale range from 0 to 20. It shows the level of
experienced everyday stress related to the disease.
Statistical analysis of the result was done using SPSS,
version 12. Descriptive statistics were calculated for all
variables. Student t-test was calculated to determine the
differences between groups.
Results
A total of 85 patients were enrolled in the study. Over-
all 65.8% (n=56) were male and 34.2% (n=29) were fe-
male. Patients were 13 to 25 years old, with the average
age being 19 years. 46 were moderate and 39 severe acne
patients. From 46 moderate acne patients, 20 were trea-
ted with isotretinoin 1 mg/kg per day, and 26 were con-
trol group treated with vitamin C 500 mg per day. From
39 severe acne patients 21 were treated isotretinoin 1
mg/kg per day and 18 were control group treated with vi-
tamin C 500 mg per day.
To investigate the possible influence of isotretinoin
on psychological status of our patients, we compared pa-
tients on isotretinoin with the control group taking vita-
min C, and we did the comparison separately for moder-
ate and severe acne patients. The comparison was made
during the 8th week of therapy and 4 weeks after the
completion of therapy.
We compared patients during the therapy to detect
possible changes in psychological status on time, in order
to stop the treatment with isotertionoin if needed. Pa-
tients with moderate acne show low level of depressive
symptoms, low anxiety and low reactive anxiety to acne
(Table 1). In moderate acne patients there was no signifi-
cant difference between the patients taking isotretinoin
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TABLE 2
THE COMPARISON OF ISOTRETINOIN GROUP AND CONTROL
GROUP AMONG MODERATE ACNE PATIENTS ON DIFFERENT
MEASURES OF PSYCHOLOGICAL STATUS DURING THE 8TH
WEEK OF TREATMENT, T-TEST FOR INDEPENDENT GROUPS
t df p
BDI 0.103 43 0.919
MPS 1.233 44 0.224
STAI – s 0.861 44 0.394
STAI – t 0.512 43 0.611
APSEA 1.296 43 0.202
TABLE 1
RESULTS ON DIFFERENT MEASURES OF PSYCHOLOGICAL
STATUS IN ISOTRETINOIN GROUP AND CONTROL GROUP
AMONG MODERATE ACNE PATIENTS DURING THE 8TH WEEK
OF TREATMENT
TEST GROUP N X SD
BDI Isotretinoin 19 4.00 4.910
Control 26 4.15 4.986
MPS Isotretinoin 20 41.40 27.021
Control 26 30.35 32.325
STAI – s Isotretinoin 20 33.35 7.686
Control 26 35.96 11.746
STAI – t Isotretinoin 19 37.42 8.474
Control 26 35.77 12.028
APSEA Isotretinoin 19 42.16 16.122
Control 26 36.65 12.393
and the control group on any of the psychological tests
during the treatment (Table 2).
Patients with severe acne also showed good psycho-
logical status with low level of depression and anxiety
(Table 3). There was no difference between patients on
isotretinoin and control group in severe acne patients on
any of the measures of psychological status (Table 4).
None of the patients in isotretinoin group (both among
moderate and severe acne patients) showed significant
symptoms of depression or anxiety during the 8th week
and all of them were able to continue with therapy. Four
weeks after the treatment patients who used isotretinoin
were compared with control group once again to check
for the possible cumulative influence of isotretinoin on
psychological status. After the end of the treatment, all
patients showed improvement on psychological status,
low level of both depression and anxiety (Table 5 and 7).
In moderate acne patients there was no difference be-
tween patients on isotretinoin and control group on any
of the measures of psychological status (Table 6). There
was no difference between patients on isotretinoin and
control group in severe acne patients either (Table 7).
To double check the possible influence of isotretinoin
on psychological status we compared results on psycho-
logical tests for all patients taking isotretinoin before
and after the therapy. Among the patients taking iso-
tretinoin, before the treatment, the mean score on BDI
was 7.36, on STAI 37.36, on MPS 42.05 and on APSEA
46.45. All results mentioned indicate good psychological
functioning with minimal number of depressive symp-
toms, low anxiety and mild reactive anxiety as a reaction
to acne. Even though mean results on all tests show im-
provement after the therapy (BDI=4.18; STAI=34.74;
MPS=32.87; APSEA=41.03), there was no statistically
significant difference between the results before and af-
ter the therapy on any of the measures of psychological
status. The present research illustrated that the isotre-
tinoin treatment does not cause psychological disorder in
acne patients (Table 8).
Discussion
The aim of this study was to investigate depression
and anxiety in facial acne patients. The adverse effect of
acne upon the patient’s psychological state has been ob-
served by many authors. However, most studies have
considered the patients with severe, generally cystic
acne10. Despite the broad range of available therapies for
acne, relatively few studies have assessed the impact of
treatment upon the psychological functioning11. From a
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TABLE 3
RESULTS ON DIFFERENT MEASURES OF PSYCHOLOGICAL
STATUS IN ISOTRETINOIN GROUP AND CONTROL GROUP
AMONG SEVERE ACNE PATIENTS DURING THE 8TH WEEK OF
TREATMENT
TEST GROUP N X SD
BDI Isotretinoin 21 5.43 5.464
Control 18 8.17 6.888
MPS Isotretinoin 21 39.05 26.009
Control 17 50.18 38.767
STAI – S Isotretinoin 21 37.71 10.598
Control 18 37.61 12.035
STAI – T Isotretinoin 21 38.33 11.804
Control 17 39.29 12.593
APSEA Isotretinoin 21 47.38 20.084
Control 18 46.89 18.464
TABLE 4
THE COMPARISON OF ISOTRETINOIN GROUP AND CONTROL
GROUP AMONG SEVERE ACNE PATIENTS ON DIFFERENT MEA-
SURES OF PSYCHOLOGICAL STATUS DURING THE 8TH WEEK
OF TREATMENT, T-TEST FOR INDEPENDENT GROUPS
t df p
BDI 1.384 37 0.175
MPS 1.056 36 0.298
STAI – S 0.028 37 0.977
STAI – T 0.242 36 0.810
APSEA 0.079 37 0.937
TABLE 5
RESULTS ON DIFFERENT MEASURES OF PSYCHOLOGICAL
STATUS IN ISOTRETINOIN GROUP AND CONTROL GROUP
AMONG MODERATE ACNE PATIENTS 4 WEEKS AFTER THE
END OF THE TREATMENT
TEST TREATMENT N X SD
BDI Isotretinoin 20 3.65 5.354
Control 26 3.27 5.583
MPS Isotretinoin 20 33.80 26.971
Control 26 30.27 34.741
STAI – S Isotretinoin 20 32.40 9.605
Control 26 33.35 11.384
STAI – T Isotretinoin 19 37.05 10.113
Control 26 34.96 11.626
APSEA Isotretinoin 18 41.17 14.569
Control 26 34.73 14.847
TABLE 6
THE COMPARISON OF ISOTRETINOIN GROUP AND CONTROL
GROUP AMONG MODERATE ACNE PATIENTS ON DIFFERENT
MEASURES OF PSYCHOLOGICAL STATUS 4 WEEKS AFTER THE
END OF THE TREATMENT, T-TEST FOR INDEPENDENT GROUPS
t df p
BDI 0.233 44 0.817
MPS 0.375 44 0.709
STAI – S 0.299 44 0.767
STAI – T 0.629 43 0.533
APSEA 1.424 42 0.162
clinical perspective, the majority of acne patients have
moderate disease. The acne patients are mainly adoles-
cents and young adults who are more vulnerable to the
cosmetic impact of their illness and can provoke signifi-
cant emotional burden for the patient. In this study we
evaluated psychological factors, depression and anxiety,
among the groups of patients with moderate to severe fa-
cial acne and prospectively examined their relation to
treatment with isotretinoin. In the past, isotretinoin was
traditionally reserved for severe acne only, but today it is
indicated in acne unresponsive to other therapy.
Each patient was tested with psychological question-
naires before the beginning of the treatment, during the
8th week of treatment, and at the end of 4th week after
the completion of treatment. The psychological question-
naires included the MPS, BDI, STAI and APSEA tests.
These tests measure common reaction to acne, depres-
sion and anxiety.
The greatest variations were observed before and af-
ter the treatment finished. Among our patients, the aver-
age result on BDI before treatment was 7.35. Most of the
patients had the results indicating minimal number of
depressive symptoms. At the end of treatment isotreti-
noin the same test was 4.17, which is lower, but the dif-
ference was not statistically significant. It was demon-
strated in the literature demonstrate that patients with
acne suffer from emotional distress and psychological
problems caused by their disease when compared to peo-
ple with healthy skin; however impairment is not corre-
lated with the objective severity of acne2. On the other
hand, Kellet and Gawkrodger6 in their study reported
that acne patients reported relatively poor psychological
disorders in comparison with other medical patients
groups. This result is in line with our findings, since we
didn’t find a strong emotional reaction to acne among
our patients.
Some authors have described depressive symptoms
during the treatment with isotretinoin3. This is the rea-
son why we used BDI test, which was very important for
monitoring depressive symptoms during the treatment.
Acne vulgaris is disease which occurs primarily in young
people, at a time when they are undergoing a great psy-
chological change – during puberty. Therefore it was very
important to stop the therapy with isotretinoin on time if
any depressive or anxiety symptoms should occur. The
results in this study obtained in moderate and severe
acne patients on the different psychological tests during
the treatment did not indicate the existence of psycholog-
ical symptoms, so that all our patients were able to com-
plete the treatment with isotretinoin. Our results corre-
lated with the findings from literature which suggested a
positive effect of isotretinoin on the manner the acne pa-
tients personally viewed themselves shortly after com-
mencement of treatment. Isotretinoin treatment reduced
the level of depressive symptoms what may be explained
by the fact that the patients had fewer skin lesions12.
At the last follow-up, at the end of the treatment, the
tests scores showed only improvement in depression, not
an increase in the number of depressive symptoms both
in the isotretinoin group and in the control group. The
isotretinoin group had a decreased level of symptoms af-
ter treatment. Our study indicated that there are no
more depressive symptoms in the isotretinoin treatment
group when compared to the control group at the end of
the treatment. In his study, Cooper described that pa-
tients after the treatment with isotretinoin were in re-
mission from acne and had non-significant reduction in
anxiety13. In this study, we showed that acne had a rela-
tively small impact on depression and anxiety, especially
in patients treated with isotretinoin. The use of isotre-
tinoin in the treatment of moderate to severe acne did
not increase depressive symptoms. On the contrary, our
study showed that isotretinoin treatment of acne does
not lead to occurrence of depressive symptoms. Our par-
ticipants were recruited from clinic outpatients seeking
medical treatment for their moderate to severe acne and
most of them were male. The gender difference may sug-
gest the final result of the study, because women are
more likely to experience greater psychological difficul-
ties than male. However, our results suggest that the
isotretinoin treatment has a general positive effect upon
the manner in which the acne patients perceived them-
selves. Welp and Gieler14 and Medanski15 did not find a
significant correlation between objective clinical findings
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TABLE 7
RESULTS ON DIFFERENT MEASURES OF PSYCHOLOGICAL
STATUS IN ISOTRETINOIN GROUP AND CONTROL GROUP
AMONG SEVERE ACNE PATIENTS 4 WEEKS AFTER THE END
OF THE TREATMENT
TEST TREATMENT N X SD
BDI Isotretinoin 21 5.86 5.918
Control 18 8.94 8.881
MPS Isotretinoin 21 38.71 29.311
Control 18 52.72 40.287
STAI – S Isotretinoin 21 36.24 10.549
Control 18 38.56 12.133
STAI – T Isotretinoin 21 36.81 10.524
Control 18 41.44 12.775
APSEA Isotretinoin 21 47.86 18.402
Control 18 47.56 18.478
TABLE 8
THE COMPARISON OF ISOTRETINOIN GROUP AND CONTROL
GROUP AMONG SEVERE ACNE PATIENTS ON DIFFERENT MEA-
SURES OF PSYCHOLOGICAL STATUS 4 WEEKS AFTER THE END
OF THE TREATMENT, T-TEST FOR INDEPENDENT GROUPS
t df p
BDI 1.294 37 0.204
MPS 1.254 37 0.218
STAI – S 0.638 37 0.527
STAI – T 1.243 37 0.222
APSEA 0.051 37 0.960
and significant psychometric variables which complies
with our results. Patients with severe acne may feel less
disfigured if they are accepted by their environment and
are given a steadfast self-image because of other abilities
and a special personality16,17.
Conclusion
We examined the depressive symptoms and anxiety
among moderate and severe acne patients. Our data ob-
tained through clinical psychiatric interviews and stan-
dard questionnaires demonstrates that patients with mo-
derate to severe acne did not suffer from significant
psychological problems (depression and anxiety). This is
contrary to previous observation that patients with dis-
figuring acne experience depression and other psycholog-
ical problems. The use of isotretinoin in the treatment of
moderate to severe acne did not increase the symptoms
of depression and anxiety. Treatment of acne with iso-
tretinoin had better results and improves depressive
symptoms. The reason for that may lay in good effects
isotretinoin has on the illness and correlations to the pa-
tient’s emotional reaction.
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PSIHOLO[KI UTJECAJ LIJE^ENJA ISOTRETINOINOM U BOLESNIKA S UMJERENO TE[KIM
I TE[KIM OBLIKOM ACNE VULGARIS
S A @ E T A K
Bolesnici s acne vulgaris pokazuju razli~it stupanj psiholo{kih poreme}aja. Emocionalni utjecaj akni naru{avanjem
vanjskog izgleda je upitan. Naj~e{}e reakcije na pojavu akni su depresija i anksioznost, a i izotretinoin, kao najbolji
izbor u lije~enju akni, mo`e dovesti do pojave simptoma depresije. Cilj na{eg istra`ivanja bio je ispitati psiholo{ki status
u bolesnika s umjereno te{kim i te{kim oblikom acni vulgaris i usporediti bolesnike lije~ene izotretinoinom s onima koji
su uzimali vitamin C. U istra`ivanju je bilo uklju~eno 85 bolesnika s acne vulgaris. Rezultati istra`ivanja ne upu}uju na
signifikantnu povezanost upotrebe izotretinoina i psiholo{kog efekta lijeka.
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